Evercore Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $60
UBS Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $108
Moderna Is Maintained at Buy by UBS
Moderna Analyst Ratings
Piper Sandler Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $115
TD Cowen Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $60
Moderna Analyst Ratings
Moderna Analyst Ratings
Jefferies Financial lowers Moderna's target price to $55.
Redburn Atlantic Adjusts Moderna's Price Target to $73 From $102, Keeps Neutral Rating
Goldman Sachs Adjusts Price Target on Moderna to $130 From $139
Gritstone Downgraded by Jones, B. Riley Over Cancer Vaccine Data
Evercore ISI Adjusts Price Target on Moderna to $120 From $105, Maintains In Line
Deutsche Bank Cuts Moderna Price Target to $75 From $80
RBC Capital Reiterates Sector Perform on Moderna, Maintains $75 Price Target
Moderna Analyst Ratings
RBC Capital Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $75
Goldman Sachs Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $139
Goldman Sachs Maintains Buy on Moderna, Lowers Price Target to $139
Moderna Is Maintained at Overweight by Barclays